Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Sarepta (SRPT) SRP-9001 Safety Issue Appears in FDA's FAERS System - Bloomberg
August 8, 2019 12:10 PM EDTSarepta's (NASDAQ: SRPT) SRP-9001 Safety Issue Appears in FDA's FAERS System - Bloomberg
Sarepta Therapeutics (SRPT) Tops Q2 EPS by 54c
August 7, 2019 5:38 PM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.83), $0.54 better than the analyst estimate of ($1.37). Revenue for the quarter came in at $94.7 million versus the consensus estimate of $90.94 million.
As we pass through mid-2019, we are very pleased to announce strong performance and solid execution against our goals. EXONDYS 51®(eteplirsen) continues to perform, with second quarter sales at $94.7 million, 29% growth quarter over same quarter last year. In our RNA franchise, we... More
